Core Insights - Cardio Diagnostics Holdings, Inc. will host an investor conference call on February 18, 2026, at 3 p.m. Central Time to discuss its precision molecular approach to cardiovascular disease prevention and early detection [1] - The call will cover updates on commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent clinical data, reimbursement progress, and strategic growth initiatives [1] Company Overview - Cardio Diagnostics is a precision cardiovascular medicine company utilizing epigenetics, genetics, and artificial intelligence to enhance the prevention and detection of cardiovascular disease [1] - The company aims to make cardiovascular disease management more accessible, personalized, and precise through its proprietary AI-driven Integrated Genetic-Epigenetic Engine [1] Financial and Operational Updates - The Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests [1] - The company is actively pursuing strategic partnerships, including a recent collaboration with Aimil Ltd. and Dr. Lal PathLabs to launch the PrecisionCHD™ test in India [1]